Neurological Complications of COVID-19: Guillain-Barre Syndrome Following Pfizer COVID-19 Vaccine
Sadia Waheed, Angel Bayas, Fawzi Hindi, Zufe Rizvi, Patricio S Espinosa
Abstract
Since the first case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in Wuhan, China, in December 2019, Coronavirus - 19 (COVID-19) has become a global pandemic with multiple neurological complications. In December 2020, two vaccines have been approved in the United States for the prevention of COVID-19. We report a case of Guillain-Barre Syndrome (GBS) after receiving the first dose of Pfizer - COVID-19 vaccine.
Topics & Concepts
MedicineGuillain-Barre syndromeCoronavirus disease 2019 (COVID-19)PandemicSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakCoronavirusBetacoronavirusPediatricsVirologyInternal medicineOutbreakInfectious disease (medical specialty)DiseasePeripheral Neuropathies and DisordersLong-Term Effects of COVID-19SARS-CoV-2 and COVID-19 Research